beta amyloid

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research [1] [2].

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Anti-Amyloid Beta Antibody (scFv59) is a human-derived antibody produced in CHO cells that targets Amyloid-β. For isotype control, please refer to Human IgG1 kappa, Isotype Control.

Bapineuzumab (AAB-001) is a humanised monoclonal antibody targeting amyloid-beta (Aβ), capable of binding to the N-terminal region of both soluble and oligomeric forms of amyloid β, and is used for research into Alzheimer's disease (AD).

Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.

Remternetug is a humanized IgG1-kappa monoclonal antibody that targets the N3pGlu peptide of the amyloid beta A4 precursor protein (APP) Aβ42. It specifically binds to the pyroglutamate-modified form of Aβ, which is implicated in the aggregation of amyloid plaques [1].

Gantenerumab (R-1450) is a humanized antibody targeting amyloid-β (Aβ), used in studies of Alzheimer's disease.

Birtamimab (NEOD001) is a monoclonal antibody selectively targeting and depleting amyloid protein, used in research on light chain amyloidosis.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal immunoglobulin G1 (IgG1) antibody specifically targeting the serum amyloid P component (SAP), a protein universally found in all types of amyloid deposits, and it possesses potential anti-amyloid activity by triggering an immunotherapeutic mechanism for the clearance of amyloid fibrils through macrophage-mediated phagocytosis, which can be applied in the research of amyloid light-chain (AL) amyloidosis and other systemic amyloid diseases.

Sabirnetug is a humanized IgG2κ monoclonal antibody that specifically targets the amyloid-β (A4) precursor protein.

Donanemab (MouseIgG2b) is an anti-amyloid antibody inhibitor containing mouse IgG2b. It is utilized in Alzheimer's disease research.

MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Aβ42. It binds to and eliminates circulating Aβ peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimer's disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Donanemab (MouseIgG2a) is a monoclonal antibody of the IgG2 class, derived from mice, and utilized in the research of Alzheimer's disease.

Velaprumig is a monoclonal antibody that targets human CD99, CCL25, and anti-human Aβ (Aβ-47F). It regulates immune cell migration, reduces β-amyloid-related pathological processes, and exhibits immunomodulatory and potential anti-Alzheimer's activity.

Dalidnetug is a humanized monoclonal antibody that targets human β-amyloid precursor protein (APP). By specifically binding to APP, Dalidnetug reduces the production of β-amyloid (Aβ), thereby demonstrating activity in clearing β-amyloid. This compound holds potential for research in Alzheimer's disease.

Oloctinebart, a humanized immunoglobulin G4-kappa (IgG4-κ) monoclonal antibody targeting LGALS3, is utilized to decrease the formation of amyloid beta oligomers [1].